Skip to main content

Table 9 Change in RI, %

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Group

Baseline

4 weeks

Absolute change

12 weeks

Absolute change

24 weeks

Absolute change

A

−2.39 ± 0.54

−3.33 ± 0.59

−0.93 ± 0.27

−4.71 ± 0.67

−2.32 ± 0.48

−6.27 ± 0.73

−3.88 ± 0.67

B

−3.18 ± 0.63

−3.49 ± 0.64

−0.31 ± 0.15

−3.89 ± 0.57

−0.71 ± 0.23

− 4.35 ± 0.57

−1.17 ± 0.32

C

−2.57 ± 0.74

−3.32 ± 0.67

−0.76 ± 0.45

−3.79 ± 0.63

−1.22 ± 0.44

− 4.82 ± 0.57

− 2.25 ± 0.56